For nearly two decades MMIT has been solely focused on solving the “what and why” of drug coverage, and has been a trusted, go-to-market partner to pharma companies, payers and providers. We believe that patients who need lifesaving treatments shouldn’t face delays because accessing drugs can be confusing. As the leading provider of market access data, analytics and insights, our expert teams of clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions. Divisions of MMIT include AIS Health, creator of the Directory of Health Plans and leading healthcare publications; Zitter Health Insights, a preeminent provider of market access insights and solutions for specialty drugs; RJ Health, the market leader in pricing and coding solutions for infusion drugs covered under the medical benefit; and The Dedham Group, a U.S. market access oncology and specialty therapeutics consultancy offering research, data analytics and strategy formulation services to the life sciences industry.